For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Isocitrate dehydrogenase (IDH) (EC 18.104.22.168) and (EC 22.214.171.124) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (a-ketoglutarate) and CO2.
Scope of the Report:
Specific mutations in the isocitrate dehydrogenase gene IDH1 have been found in several brain tumors including astrocytoma, oligodendroglioma and glioblastoma multiforme, with mutations found in nearly all cases of secondary glioblastomas, which develop from lower-grade gliomas, but rarely in primary high-grade glioblastoma multiforme.Patients whose tumor had an IDH1 mutation had longer survival. Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML).These mutations are known to produce (D)-2-hydroxyglutarate from alpha-ketoglutarate.(D)-2-hydroxyglutarate accumulates to very high concentrations which inhibits the function of enzymes that are dependent on alpha-ketoglutarate.This leads to a hypermethylated state of DNA and histones, which results in different gene expression that can activate oncogenes and inactivate tumor-suppressor genes. Ultimately, this may lead to the types of cancer described above.Isocitrate dehydrogenase inhibition technology can be effectively applied to the cancer market.
The worldwide market for Isocitrate Dehydrogenase Inhibitors is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Isocitrate Dehydrogenase Inhibitors in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Aslan Pharmaceuticals
- Bristol-Myers Squibb
- Daiichi Sankyo
- Philogen S.p.A.
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- IDH1 Mutant Medullary Malignant Tumor
- IDH2 Mutant Medullary Malignant Tumor
Market Segment by Applications, can be divided into
- DH Inhibitor
- FLT3 Inhibitor
- Hedgehog Pathway Inhibitor
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Isocitrate Dehydrogenase Inhibitors product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Isocitrate Dehydrogenase Inhibitors, with price, sales, revenue and global market share of Isocitrate Dehydrogenase Inhibitors in 2017 and 2018.
Chapter 3, the Isocitrate Dehydrogenase Inhibitors competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Isocitrate Dehydrogenase Inhibitors breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Isocitrate Dehydrogenase Inhibitors market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Isocitrate Dehydrogenase Inhibitors sales channel, distributors, customers, research findings and conclusion, appendix and data source.